Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN® in Pediatric Spasticity

Contributed by: Business Wire

Logo

Tags

Health

Consumer

Teens

Neurology

Children

Pharmaceutical

Merz Therapeutics

More Like This

Merz Therapeutics Receives EU/EEA Approval for XEOMIN® for the Treatment of Pediatric Spasticity Associated With Pes Equinus

Merz Therapeutics’ Activities at ISPRM 2026 Highlight the Importance of Patient-Centric Management in Upper and Lower Limb Spasticity: From Goal Setting to Optimal Dosing for Better Patient Outcomes

Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan

Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 2026

Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right)

Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin® Delivery System for Overactive Bladder

ONWARD Medical Receives CE Mark for ARC-EX, Enabling Commercial Launch of Breakthrough Spinal Cord Stimulation System in Europe

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union